Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.

How I treat hairy cell leukemia. Blood (2009) 1.62

My treatment approach to hairy cell leukemia. Mayo Clin Proc (2012) 0.93

Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol (2014) 0.85

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood (2016) 0.77

Efficacy and Safety of Cladribine: Subcutaneous versus Intravenous Administration in Hairy Cell Leukemia Patients. Mediterr J Hematol Infect Dis (2015) 0.75

Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. Haematologica (2014) 0.75

Hairy cell leukemia - immunotargets and therapies. Immunotargets Ther (2014) 0.75

Hairy Cell Leukaemia in Oman: Four cases. Sultan Qaboos Univ Med J (2008) 0.75

Current and emerging treatment options for hairy cell leukemia. Onco Targets Ther (2015) 0.75

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol (2012) 5.75

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69

Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol (2007) 4.93

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med (2007) 4.07

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol (2008) 3.49

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood (2007) 3.15

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood (2007) 3.05

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78

First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol (2009) 2.71

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol (2010) 2.51

Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol (2003) 2.30

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood (2008) 2.17

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood (2003) 2.16

Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood (2009) 1.87

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol (2012) 1.56

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood (2012) 1.50

Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma (2007) 1.50

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol (2012) 1.50

Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma (2009) 1.44

Primary breast lymphoma - a review of the literature and report of three cases. Arch Med Sci (2011) 1.43

Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias. Acta Haematol (2015) 1.42

Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib. Leuk Lymphoma (2009) 1.41

Microscopic examination of bone marrow aspirates in malignant disorders of haematopoiesis--a comparison of two slide preparation techniques. Ann Hematol (2011) 1.38

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med (2008) 1.26

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol (2009) 1.24

BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res (2008) 1.22

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol (2014) 1.22

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood (2002) 1.18

Current and emerging treatments for chronic lymphocytic leukaemia. Drugs (2009) 1.17

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol (2012) 1.15

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol (2007) 1.13

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood (2013) 1.13

ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle (2006) 1.12

High-resolution human leukocyte antigen allele and haplotype frequencies of the Polish population based on 20,653 stem cell donors. Hum Immunol (2011) 1.11

Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep (2008) 1.10

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol (2012) 1.10

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood (2012) 1.09

Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke (2009) 1.09

Comment on "Venous thrombosis: who should be screened for thrombophilia in 2014?". Pol Arch Med Wewn (2014) 1.05

The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell Transplant (2011) 1.02

Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol (2008) 1.00

Hodgkin's lymphoma and tuberculosis coexistence in cervical lymph nodes. Leuk Lymphoma (2005) 0.99

The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells. Cell Cycle (2012) 0.99

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol (2010) 0.99

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer (2015) 0.98

The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer (2013) 0.98

How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk (2011) 0.98

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood (2006) 0.97